BioNano Genomics Inc vs Occidental Petroleum Corporation — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Occidental Petroleum Corporation trades at $53.25 (market cap $54.28B). The key difference: Occidental Petroleum Corporation is far larger — about 4112.1× BioNano Genomics Inc's market cap, and Occidental Petroleum Corporation pays a 1.91% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | OXY | |
|---|---|---|
Market Cap | $13.20M | $54.28B |
Sector | Health | Energy |
52-Week High | $4.92 | $66.24 |
52-Week Low | $1.09 | $38.92 |
Enterprise Value | $15.81M | $75.36B |
Dividend Yield | — | 1.91% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Occidental Petroleum (OXY) trades at $54.81, up 3.63% with bullish technical signals and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust profitability with 22.42% net income margin and 14.04% ROE, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Analyst consensus is positive with 50% buy ratings and $66.14 price target, while recent news highlights operational improvements and geopolitical tailwinds from higher oil prices.
OXY presents a compelling investment case with earnings outperformance, debt reduction progress, and favorable oil price environment, but faces risks from commodity volatility and execution challenges in carbon capture initiatives. The stock's current valuation at 74x P/E requires sustained earnings growth to justify further upside potential.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →